Key words: European Paediatric Regulation, Medicinal products, Paediatric use, Drug development
The European Commission has produced a report on the experience gained in the application
of Regulation (EC) No. 1901/2006 concerning medicinal products for paediatric
use. Six years after the entry into force of the Regulation, the report describes the stages
of its implementation, the results achieved, lessons learned and future prospects, taking
into account the fact that, in view of the time required for drug development, not less
than ten years will be needed to understand all the repercussions. The paper concludes
with a note of optimism showing that: a) the development for paediatric use has become
an integral part of the overall process of drug development in the EU; b) new medicines
with paediatric indications and dosage forms appropriate to age groups have been approved;
c) the large number of approved paediatric investigation plans indicates that
other drugs are still being processed.
Vuoi citare questo contributo?
L'accesso è riservato agli abbonati
alla rivista che si siano registrati.
Per accedere all'articolo in formato full text è necessario inserire nella casella di login username e password.
L'immissione di nuovi contenuti è riservata ai soli utenti registrati